Panbela announces sponsored research agreement to evaluate polyamine metabolic inhibitor therapy in combination with car-t cell therapy

Minneapolis, june 13, 2023 (globe newswire) -- panbela therapeutics, inc . (nasdaq: pbla), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has entered into a sponsored research agreement with the university of texas md anderson cancer center for the evaluation of polyamine metabolic inhibitor therapies in combination with car-t cell therapies in preclinical models. the initial goal of these studies will be to ascertain if eflornithine and/or ivospemin treatment will augment car-t mediated cytotoxicity against cd19+ large b-cell lymphoma (lbcl) cell lines.   recently, a metabolite panel primarily consisting of polyamines was identified as predictive of poor response to anti-cd19 car t-cell therapy in relapsed refractory lbcl. additionally, the polyamine (pa) uptake transport system is upregulated in lbcl and multiple myeloma (mm). together, this suggests the potential for a polyamine targeted therapy in combination with car-t therapies.
PBLA Ratings Summary
PBLA Quant Ranking